ZIM
MLNT

Zacks Investment Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Zacks Investment Management’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-152,787
Closed -$542K – 645
2019
Q1 		$542K Buy
+152,787
New +$829K 0.01% 450

Other funds holding MLNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Zacks Investment Management's MLNT Position: Q2 2019 in Review

Zacks Investment Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2019, closing a stake of 152,787 shares — an estimated $542K sold.

Zacks Investment Management first reported a position in MLNT in Q1 2019 and held it in 1 quarter. The position peaked at $542K in Q1 2019. 53 funds tracked by Wall St. Rank hold MLNT as of Q2 2019.

  • Zacks Investment Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Zacks Investment Management sold 152,787 Melinta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $542K.
  • Zacks Investment Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Zacks Investment Management's Melinta Therapeutics, Inc. Common Stock position peaked at $542K in Q1 2019.
  • 53 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Zacks Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.